Irbesartan
Based on 8 publication(s) in Google Scholar
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.95%
- CAS No.: 138402-11-6
- Formule: C25H28N6O
- Masse moléculaire:428.53
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Nephrotoxicity Compound Library
HY-L229
-
Lactylation Compound Library
HY-L249
-
Classic FDA-Approved Drug Library
HY-L261
Publications Citing Use of MedChemExpress (MCE) Irbesartan
More- J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
- J Immunother Cancer. 2026 Mar 25;14(3):e012426. [Abstract]
- Int J Biol Macromol. 2024 May;266(Pt 1):131175. [Abstract]
- Phytother Res. 2026 Feb;40(2):812-828. [Abstract]
- Atherosclerosis. 2019 Sep:288:124-136. [Abstract]
- FASEB J. 2026 Jan 31;40(2):e71433. [Abstract]
- Biomedicines. 2021 Dec 2;9(12):1820. [Abstract]
- Saudi Pharm J. 2022 Mar;30(3):237-244. [Abstract]
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
IF
-
IF
Voir tous les produits spécifiques à Isoform Angiotensin Receptor
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HASMC | IC50 |
0.32 μM
Compound: SR-47436
|
Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose-dependent manner
Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose-dependent manner
|
[PMID: 8576904] |
| HEK293 | IC50 |
>500 μM
Compound: irbesartan
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
|
[PMID: 23241029] |
| PLC-PRF-5 | IC50 |
3 nM
Compound: Irbesartan
|
In vitro antagonist activity, Inhibition of angiotensin II (50 nM) mediated increase in cytosolic [Ca2+] conc. in PLC-PRF-5 cells
In vitro antagonist activity, Inhibition of angiotensin II (50 nM) mediated increase in cytosolic [Ca2+] conc. in PLC-PRF-5 cells
|
[PMID: 10893306] |
Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro[1].
Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro[1].
Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD4+ T cells
-
Concentration:0, 20, 40 and 60 μM
-
Incubation Time:48 h
-
Result:Exerted no obvious effect on viability of CD4+T cells.
Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II[1].
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:50 mg/kg
-
Administration:oral gavage; 50 mg/kg/d; once daily
-
Result:Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.
Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.
Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:20 μM
-
Administration:20 μM; for 3 h
-
Result:Downregulated renal CCL20, CCL22 and CCL27 concentrations.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 138402-11-6
-
Appearance Solid
-
Masse moléculaire 428.53
-
Formule C25H28N6O
-
Color White to off-white
-
SMILES
O=C1N(CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)C(CCCC)=NC15CCCC5
-
Synonyms
SR-47436; BMS-186295
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
J Exp Clin Cancer Res
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. [Abstract]2023 May 4;42(1):111. PMID: 37143164
Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
The apoptosis of organoids treated with GEM (0.8 μM) and Irbesartan (1 μM) for 72 h was determined by western blot for cleaved-caspase 3/7. Tubulin was used as loading control.
Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
Organoids were treated with vehicle, GEM (0.8 μM), irbesartan (1 μM) and GEM (0.8 μM) plus irbesartan (1 μM), followed by continually monitoring PDAC organoid apoptosis by real-time caspase3/7 probe imaging for 72 h.
Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
Irbesartan (20 mg/kg; po; twice a week) plus GEM significantly reduced the weight of pancreatic tumor.
Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
Irbesartan (20 mg/kg; po; twice a week) induced apoptosis in mouse pancreatic tumor tissues.
Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
Irbesartan (20 mg/kg; po; twice a week) decreased the percent of Ki67 positive cells in mouse pancreatic tumor tissues.
-
J Immunother Cancer
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [Abstract]2026 Mar 25;14(3):e012426. PMID: 41881499 -
Int J Biol Macromol
An injectable polyacrylamide/chitosan-based hydrogel with highly adhesive, stretchable and electroconductive properties loaded with irbesartan for treatment of myocardial ischemia-reperfusion injury. [Abstract]2024 May;266(Pt 1):131175. PMID: 38552696 -
Phytother Res
Saikosaponin D Regulates HK2-Mediated Glycolytic Lactate Signaling to Alleviate CKD-Induced Renal Fibrosis. [Abstract]2026 Feb;40(2):812-828. PMID: 41508401 -
Atherosclerosis
RhoGDI stability is regulated by SUMOylation and ubiquitination via the AT1 receptor and participates in Ang II-induced smooth muscle proliferation and vascular remodeling. [Abstract]2019 Sep:288:124-136. PMID: 31362179 -
FASEB J
Hirudin Ameliorates Kidney Injury in DKD Mice by Decreasing SOD2 β-Hydroxybutyrylation Mediated ROS Level and NLRP3 Inflammasome Formation. [Abstract]2026 Jan 31;40(2):e71433. PMID: 41546551 -
Biomedicines
2021 Dec 2;9(12):1820. PMID: 34944635 -
Saudi Pharm J
Study of influence of Catha edulis (Khat) chewing on oral pharmacokinetics of irbesartan in rats using a newly developed HPLC-UV method. [Abstract]2022 Mar;30(3):237-244. PMID: 35498225
Solvant et solubilité
DMSO : 100 mg/mL (233.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Schupp M, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004 May 4;109(17):2054-7. Epub 2004 Apr 26. [Content Brief]
[2]. Ruiz E, et al. Importance of intracellular angiotensin II in vascular smooth muscle cell apoptosis: inhibition by the angiotensin AT1 receptor antagonist irbesartan. Eur J Pharmacol. 2007 Jul 19;567(3):231-9. Epub 2007 Apr 6. [Content Brief]
[3]. Yong Zhong, et al. Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension. Int Immunopharmacol [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3336 mL | 11.6678 mL | 23.3356 mL | 58.3390 mL |
| 5 mM | 0.4667 mL | 2.3336 mL | 4.6671 mL | 11.6678 mL | |
| 10 mM | 0.2334 mL | 1.1668 mL | 2.3336 mL | 5.8339 mL | |
| 15 mM | 0.1556 mL | 0.7779 mL | 1.5557 mL | 3.8893 mL | |
| 20 mM | 0.1167 mL | 0.5834 mL | 1.1668 mL | 2.9169 mL | |
| 25 mM | 0.0933 mL | 0.4667 mL | 0.9334 mL | 2.3336 mL | |
| 30 mM | 0.0778 mL | 0.3889 mL | 0.7779 mL | 1.9446 mL | |
| 40 mM | 0.0583 mL | 0.2917 mL | 0.5834 mL | 1.4585 mL | |
| 50 mM | 0.0467 mL | 0.2334 mL | 0.4667 mL | 1.1668 mL | |
| 60 mM | 0.0389 mL | 0.1945 mL | 0.3889 mL | 0.9723 mL | |
| 80 mM | 0.0292 mL | 0.1458 mL | 0.2917 mL | 0.7292 mL | |
| 100 mM | 0.0233 mL | 0.1167 mL | 0.2334 mL | 0.5834 mL |
Irbesartan Related Classifications
HY-B0202 Related Classifications
Powered by Bioz